Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 4/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13275159 | 0.93 | KLKB1 (0.38) | CHRM4KLKB1VNN1CACNA2D1CCR3 | |
| SCHEMBL13275458 | 0.90 | IMPDH2 (0.40) | CHRM4KLKB1CACNA2D1CCR3KMT2A | |
| SCHEMBL13274789 | 0.88 | MET (0.45) | CHRM4METCACNA2D1CCR3HTT | |
| SCHEMBL13465659 | 0.85 | HPGD (0.41) | METKMT2A | |
| SCHEMBL13275332 | 0.84 | KDM4E (0.39) | METKMT2A | |
| SCHEMBL13274968 | 0.84 | MET (0.37) | KLKB1MET | |
| SCHEMBL13465816 | 0.84 | PARP1 (0.38) | KLKB1CACNA2D1CCR3KMT2AHTR2A | |
| SCHEMBL13274862 | 0.84 | ROCK2 (0.36) | CHRM4KLKB1CACNA2D1CCR3HTT | |
| SCHEMBL13449332 | 0.84 | IMPDH2 (0.40) | KLKB1CCR3 | |
| SCHEMBL13449331 | 0.83 | PARP1 (0.49) | METKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | claimed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | claimed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | CHRM4 4663/4885KLKB1 2827/4885MET 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.